Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.

Abstract

BACKGROUND:

To analyze the ability of bevacizumab (Avastin) eye drops to inhibit corneal neovascularization.

DESIGN:

interventional case series involving five patients (age: 42 +/- 14 years).

METHODS:

Patients with aggressive corneal neovascularisation not responding to conventional therapy were treated with bevacizumab (Avastin) eye drops (5x/day; 5 mg/ml) for 0.5 to 6 months (mean: 3.6 +/- 2; four patients with limbal stem cell deficiency [three due to chemical burns and one inherited] and one after perforating keratoplasty).

RESULTS:

Bevacizumab eye drops were well tolerated without obvious corneal side-effects. All five patients showed a reduction in the neovascularized area (decrease 48 +/- 28%; 13-75%).

CONCLUSIONS:

Bevacizumab eye drops seem to inhibit corneal neovascularization without obvious corneal epithelial side-effects.

• Authors: Felix Bock, Yanyan König, Friedrich Kruse, Martin Baier, Claus Cursiefen
• Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (Graefes Arch Clin Exp Ophthalmol) Vol. 246 Issue 2 Pg. 281-4 (Feb 2008) ISSN: 0721-832X [Print] Germany
• PMID: 17934753 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Ophthalmic Solutions
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Administration, Topical
• Adult
• Aged
• Angiogenesis Inhibitors (administration & dosage)
• Antibodies, Monoclonal (administration & dosage)
• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Corneal Neovascularization (pathology, prevention & control)
• Female
• Humans
• Male
• Middle Aged
• Ophthalmic Solutions (administration & dosage)
• Vascular Endothelial Growth Factor A